SequelSEC

RELMADA THERAPEUTICS, INC. RLMD

Pharmaceutical Preparations · CIK 0001553643 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$682
Fiscal year ended 2014-02-28
Operating income
-$3.12K
Fiscal year ended 2014-02-28
Free cash flow
Unavailable
Fiscal year ended 2014-02-28

RELMADA THERAPEUTICS, INC. (RLMD) reported revenue of $682 for the fiscal year ended 2014-02-28. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from RELMADA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

RELMADA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-02-28
Revenue$682
Cost of revenue$685
Gross profit-$3
Operating income-$3.12K
Net incomeUnavailable
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$3.12K
Selling & marketingUnavailable

Balance

RELMADA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-02-28
Cash & equivalentsUnavailable
Total assets$10.00K
Current assets$8.75K
Total liabilitiesUnavailable
Current liabilities$41.16K
Total equity incl. NCI-$31.16K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$41.16K

Cash flow

RELMADA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-02-28
Operating cash flowUnavailable
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

RELMADA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2014-02-28
Free cash flowUnavailable
Gross margin-0.4%
Operating margin-458.1%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.21x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RLMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.